Lower GI 2017

…beyond EGFR- and VEGF-Inhibition

Author/ Group

Mode of Action

Drug/Schedule

Comments

Phase I (n=9); (DLT: diarrhea)

Proteasome Inhibition

O‘Neil; 2010

Bortezomib + 5-FU/RT

Histone Deactylase Inhibition

Phase I (n=17) (DLT: fatique, anorexia, diarrhea) Phase I (n=25); pCR 28% (DLT: skin, nausea) Phase I (n=11) pCR 27% (DLT: cholangitis, liver- enzymes) Phase II (n=40) pCR 15% (Grade 4: 3% neutropenia; Grade 3: diarrhea

Vorinostat + palliative RT 30 Gy in 10#)

Ree; 2010

PARP Inhibition

Czito; 2015

Veliparil + Cape/RT

PI3-K/AKT Inhibition

Buijsen; 2013

Nelfinavir + Cape/RT

RAF/MEK/ERK and VEGF-R

Moos; 2014

Sorafenib + Cape/RT